Saturday, June 25, 2022

Qualigen Therapeutics Inc. [QLGN] stock for 17,100 USD was purchased by Poirier Michael S.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Qualigen Therapeutics Inc. shares valued at $17,100 were purchased by Poirier Michael S. on Jun 22. At $0.57 per share, Poirier Michael S. acquired 30,000 shares. The insider’s holdings grew to 199,202 shares worth approximately $0.11 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, BROIDRICK AMY S. purchased 30,000 shares, netting a total of over 18,600 in proceeds. Following the buying of shares at $0.62 each, the insider now holds 34,500 shares.

Before that, Kruger Kurt H had added 8,000 shares to its account. In a trade valued at $9,800, the Director bought Qualigen Therapeutics Inc. shares for $1.23 each. Upon closing the transaction, the insider’s holdings increased to 8,000 shares, worth approximately $10080.000000000002.

As published in a research note from JP Morgan on May 25, 2022, Equitable Holdings Inc. [EQH] has been rated up from a Neutral to an Overweight and the price target has been revised to $36. This represents a 26.22% premium over Wednesday’s closing price. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in late May. As of January 26, 2022, Jefferies has initiated its “Buy” rating for EQH. Earlier on December 03, 2021, Goldman initiated its rating. Their recommendation was “a Buy” for EQH stock.

Analyzing QLGN’s Price Performance

On Wednesday, Qualigen Therapeutics Inc. [NASDAQ: QLGN] plunged -1.92% to $0.56. The stock’s lowest price that day was $0.5555, but it reached a high of $0.597 in the same session. During the last five days, there has been a drop of approximately -4.22%. Over the course of the year, Qualigen Therapeutics Inc. shares have dropped approximately -48.08%. Shares of the company reached a 52-week high of $1.5200 on 04/12/22 and a 52-week low of $0.4500 on 05/11/22. A 50-day SMA is recorded $0.5794, while a 200-day SMA reached $0.9193. Nevertheless, trading volume fell to 0.14 million shares from 0.2 million shares the previous day.

Support And Resistance Levels for Qualigen Therapeutics Inc. (QLGN)

According to the 24-hour chart, there is a support level at 0.5417, which, if violated, would cause prices to drop to 0.5278. In the upper region, resistance lies at 0.5832. The next price resistance is at 0.6108. RSI (Relative Strength Index) is 46.49 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0217, which suggests the price will decrease in the coming days. Percent R is at 95.17%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Which companies own the most shares of Qualigen Therapeutics Inc. (QLGN)?

According to The Vanguard Group, Inc. filings, the company currently owns 1,150,593 shares, which is about 3.26% of the total QLGN shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 1150593.0 shares. With the completion of the buy, BlackRock Fund Advisors’s stake is now worth $184,450. Geode Capital Management LLC reduced a 0.00% interest valued at $0.12 million while T. Rowe Price Associates, Inc. sold a -25,800 stake. A total of 124,311 shares of Qualigen Therapeutics Inc. were sold by Citadel Advisors LLC during the quarter, and 114,027 by Renaissance Technologies LLC. In its current portfolio, SSgA Funds Management, Inc. holds 105,414 shares valued at $59137.0.

In terms of Qualigen Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $6.50 in the next 12 months, up nearly 1040.35% from the previous closing price of $0.57. Analysts anticipate Qualigen Therapeutics Inc. stock to reach $6.50 by 2022, with the lowest price target being $6.50. In spite of this, 1 analysts ranked Qualigen Therapeutics Inc. stock as a Buy at the end of 2022.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam